Kornimate/medical-research-clean huggingface dataset:
efficacy of zinc in reducing hyperbilirubinemia among high risk neonates - a double blind randomized trial

Conditions: Neonatal Jaundice

Summary: the purpose of this study is to determine the effect of 10 mg of oral zinc given daily between days 2 and 7 of life to term or near term neonates with serum bilirubin levels of more than 6 mg/dl at 24 ± 6 hours of life on hyperbilirubinemia and phototherapy.

neonatal hyperbilirubinemia is a common problem occurring in nearly 5-25% neonates.inhibition of enterohepatic circulation is one of the therapies being tried for neonatal jaundice. studies have suggested that in a neonate, the postulated enterohepatic pathway is of a magnitude that could be significant in the overall body economy of bilirubin.zinc has also been investigated for its role in decreasing the stb levels by inhibiting enterohepatic circulation. there have been animal studies which have investigated the role of zinc in decreasing the serum bilirubin levels. the mechanism proposed is that zinc salts precipitate unconjugated bilirubin from unsaturated micellar solution of bile salts and consequently inhibit the enterohepatic circulation of bilirubin. this is the first study to evaluate the role of zinc in neonatal jaundice. study design: in this randomized placebo controlled clinical trial neonates born at ≥35 wk of gestation and with total serum bilirubin ≥6mg% were given either zinc gluconate (n = 148) or placebo (n = 146) in a dose of 10mg per day between days 2 and 7 of life. jaundice was assessed clinically and total serum bilirubin estimated using spectrophotometry. infants were followed up clinically until discharge and then again at day 7 of life. hyperbilirubinemia was defined as total serum bilirubin ≥15mg%. results: incidence of hyperbilirubinemia was comparable in zinc and placebo groups (or 0.95, 95% ci 0.50-1.67, p=0.92). the requirement of phototherapy was similar in the two groups (or 0.81, 95% ci 0.41-1.61, p=0.55). the mean hours of phototherapy in the zinc group were also similar in the two groups (p=0.63). no significant difference with respect to mean levels of bilirubin (mg/dl) at 72±12 hours of age was observed in two groups(zinc 11.3±3.3,placebo 11.5±3.8,p=0.63). no significant adverse effects of zinc were noted. conclusion: twice daily zinc administration in a dose of 10 mg/day does not reduce hyperbilirubinemia in at risk neonates in the first week of life. .

Eligibility criteria:
inclusion criteria: * neonates born at ≥35 weeks gestation and with total serum bilirubin ≥ 6 mg/dl at 24±6 h of life. exclusion criteria: * rh incompatibility * those given exchange transfusion/ phototherapy within 24 h of age. * major gross congenital anomaly * anticipated to require neonatal intensive care or required neonatal intensive care for more than 24 h. * systemic sepsis

Keywords: neonatal jaundice zinc hyperbilirubinemia enterohepatic circulation bilirubin
awareness of families with down syndrome children about the role of physical therapy in egypt

Conditions: Down Syndrome (DS)

Summary: this study explores how much families with children who have down syndrome in egypt know about the benefits and role of physical therapy. by understanding their awareness, hope to improve education and support so that these families can better access physical therapy services that can help improve their children's quality of life.

this cross-sectional study aims to assess the awareness of families with children who have down syndrome regarding the role of physical therapy in egypt. data will be collected via a validated questionnaire distributed to family members to evaluate their knowledge and perceptions about physical therapy interventions. the study seeks to identify gaps in awareness and inform strategies for improving educational outreach and support for these families.

Eligibility criteria:
inclusion criteria: * parents/guardians of children diagnosed with ds. * egyptian residents. * consent to participate in the study * aged 18 years or older exclusion criteria: * families with children who have conditions other than ds. * participants who do not provide informed consent.

Keywords: awareness genetic disorders physical therapy egypt down syndrome
magnesium and postoperative pain

Conditions: Arthritis Knee; Magnesium Sulfate; Dexmedetomidine

Summary: with ongoing advancements in healthcare leading to prolonged life expectancy, orthopedic surgeries are increasingly performed in elderly patients. total knee arthroplasty, in particular, has been increasing with the growing demand for improved mobility and quality of life. total knee arthroplasty is performed on patients with advanced and painful osteoarthritis of the knees, but it can result in moderate to severe postoperative pain during the recovery period. to relieve anxiety or stress during surgery under regional anesthesia, sedation can be provided. dexmedetomidine is a sedative-analgesic agent acting as α2-adrenergic receptor agonist, and its analgesic effect has been well established in various procedures or surgeries. magnesium has been reported to produce important analgesic effects including the suppression of neuropathic pain, potentiation of morphine analgesia, and attenuation of morphine tolerance. although the exact mechanism is not yet fully understood, the analgesic properties of magnesium are believed to stem from regulation of calcium influx into the cell and antagonism of n-methyl-d-aspartate (nmda) receptors in the central nervous system. in this study, investigators will evaluate the reducing effect of magnesium on the post-total knee arthroplasty pain in patients sedated with dexmedetomidine under spinal anesthesia.


Eligibility criteria:
inclusion criteria: * patients who undergo total knee arthroplasty under spinal anesthesia * patients who want to sedation during the surgery * american society of anesthesiologists physical status classification 1 and 2 exclusion criteria: * general anesthesia * patients who do not want to sedation during the surgery * patients who do not receive patient controlled analgesia postoperatively * muscular disease * hypermagnesemia * atrioventricular block
propranolol in angiosarcoma

Conditions: Angiosarcoma

Summary: this is a window opportunity study of propranolol in patients with angiosarcoma. the aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate both the clinical response and histological response, without a significant delay in anti-cancer treatment.

a pilot neoadjuvant window of opportunity study will be performed to explore the activity of propranolol monotherapy in angiosarcoma. the study consists of a single arm. propranolol will be administred as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. when patients are diagnosed, standard anti-cancer treatment will be scheduled in 6 weeks while propranolol treatment can start immediately after diagnosis and will be continued until the day the standard anti-cancer treatment is started. the duration of treatment will therefore be 3-6 weeks.

Eligibility criteria:
inclusion criteria: 1. histological proof of angiosarcoma 2. patients with primary, recurrent and metastasised disease are eligible; 3. patients with a window of at least 3 weeks before surgery or systemic therapy; 4. age ≥ 18 years; 5. able and willing to give written informed consent; 6. who performance status of 0, 1 or 2; 7. evaluable disease according to recist 1.1 criteria; radiologic visible disease is not obligated in patients with cutaneous angiosarcoma 8. minimal acceptable safety laboratory values 9. anc of ≥ 1.5 x 109 /l 10. platelet count of ≥ 100 x 109 /l 11. hepatic function as defined by serum bilirubin ≤ 1.5 x uln, asat and alat ≤ 2.5 x uln 12. renal function as defined by serum creatinine ≤ 1.5 x uln or creatinine clearance ≥ 50 ml/min (by cockcroft-gault formula); 13. at least one tumor lesion accessible to safely biopsy per clinical judgement of the treating physician exclusion criteria: 1. contraindication for propranolol therapy, like severe hypotension or bradycardia, sicksinus syndrome, second or third grade heart block, cardiogenic shock, untreated heart failure, severe peripheral vascular disease asthma or other obstructive lung diseases, untreated pheochromocytoma, metabolic acidosis, prolonged fasting. 2. current treatment with β-blockade therapy. 3. any anticancer treatment within 30 days prior to receiving the first dose of investigational treatment; with the exception of hormonal therapy for breast cancer. 4. concurrent treatment with an anticancer therapy: with the exception of hormonal therapy for breast cancer. 5. patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance; 6. evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications; 7. pregnancy; 8. legal incapacity

Keywords: propranolol angiosarcoma
international multicenter study one day prevalence observational study for delirium on icu

Conditions: Delirium

Summary: an anonymous international multicenter - clinical survey, one-day observational study.

delirium is a serious complication in postoperative and critically ill patients and is independently associated with cognitive impairment at hospital discharge and with significantly higher 6-month mortality. furthermore, icu delirium is associated with more days requiring mechanically ventilation, longer icu length of stay, and longer hospital length of stay. more recently a study by pisani and co-workers' could show an association between days of delirium and mortality; - each additional day spent in delirium is associated with a 20% increased risk of prolonged hospitalization - translating to over 10 additional days - and a 10% increased risk of death.the reported prevalence of delirium in critically ill patients ranges widely from 11% to 87%. the aim of our study is to investigate the implementation rate of routine delirium assessment in european icus.

Eligibility criteria:
inclusion criteria: * patients staying in the icu on the 25th of january (one-day prevalence study) no exclusion criteria:

Keywords: delirium analgosedation icu pain implementation
randomized trial of exercise on lower extremity edema after lymphadenectomy in gynecologic cancer

Conditions: Gynecologic Cancer

Summary: the primary outcome is the change in lower extremity edema-related symptoms. secondary outcomes include the compliance rate of management guidelines for lower extremity edema, the performance rate for pelvic and lower extremity exercise.


Eligibility criteria:
inclusion criteria: * more than 18 years of age * patients who underwent pelvic lymphadenectomy * patients with suspicious pelvic cancer who finished active treatments such as chemotherapy, radiotherapy or surgery. the interval between the time of randomization and the end of the treatment should be more than 2 weeks. * the patient is able to understand the study and is willing to give written informed consent to the study * patient with edema-related symptoms such as leg heaviness, distension, tightness, pain, limited movement, or weakness etc. exclusion criteria: * severe systemic diseases causing peripheral edema, including renal disease * severe or uncontrolled cardiopulmonary disease, including implantable device such as a pacemaker * acute superficial or deep vein thrombosis * previous major surgery for lower extremities, including metallic surgical implant * local infection in the lower extremities * auto-immunological disorders or vasculitis * use of systemic corticosteroids * pregnant or currently breastfeeding * alcohol or drug abuse * uncontrolled diabetes

Keywords: lower extremity edema lower leg lymphedema lower leg edema lymphedema pelvic lymphadenectomy exercise
atrial function and supraventricular arrhythmia of the veteran athlete.

Conditions: Supraventricular Arrhythmias

Summary: supraventricular arrhythmias (including atrial fibrillation) are the most common arrhythmias of the veteran athlete and have a major impact in terms of morbidity and mortality. although moderate sports practice has been shown to decrease the occurrence of these arrhythmias, it has also been shown that very intense athletic activity is associated with an increased risk of developing atrial fibrillation. the pathophysiological mechanism is not clearly understood. however, it has already been shown that intensive sports practice leads to electrical and morphological atrial remodeling, which could be the cause of the occurrence of supraventricular arrhythmias for these athletes. for sedentary patients, two major tools predict the risk of the onset of supraventricular arrhythmia: the electrocardiogram (ecg) and transthoracic echocardiography (ett), particularly with the study of atrial function by the analysis of myocardial deformities.

no studies have tested these two tools for the evaluation of atrial remodeling of the veteran athlete to predict which ones are at risk of developing supraventricular arrhythmias. however, the identification of predictive factors would make it possible to identify at-risk athletes and thus provide them with adapted sporting practice advice and personalized follow-up. the aim of the study is to evaluate the relationship between atrial remodeling assessed by ecg and ett with the occurrence of supraventricular arrhythmia by comparing an athlete group with supraventricular arrhythmia with a control group of healthy athletes.

Eligibility criteria:
inclusion criteria: * supraventricular arrhythmia group : veteran athletes with documented paroxysmal supraventricular arrhythmias. * control group : veteran athletes without documented supraventricular arrhythmia. exclusion criteria: * any cardiopathy (valvulopathy, coronary heart disease, etc.). * minor patients, * major patients subject to legal protection (legal safeguards, guardianship) * persons deprived of their liberty * patients opposed to the use of their personal data.

Keywords: supraventricular arrhythmias veteran athlete ecg ett
remote monitoring of home exercise in peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: many patients with blockages in the arteries in their legs (peripheral arterial disease, "pad") suffer from pain in their legs when walking. exercise therapy is known to decrease pain levels as well as increase the distance that patients with pad can walk. the purpose of this study is to understand whether home exercise using a digital exercise monitoring system (livmor) with provider supervision/ feedback will improve walking distance compared to those undergoing home exercise using the same monitoring system but without provider supervision/ feedback.


Eligibility criteria:
inclusion criteria: * age \>18 * diagnosis of pad (based on abi \<0.9 in either leg or prior intervention) with mild/moderate claudication exclusion criteria: * prior above ankle amputation * wheelchair bound * inability to walk \>200m during 6 min walk test * use of walking aid other than cane * walking impairment for reason other than pad * critical limb ischemia * planned vascular surgery within next 3 months, recent surgery within past 3 months

Keywords: pad home walking remote monitoring claudication
the effect of nutrient intake on the microbiome, weight, and glucoregulation (ni-mwg)

Conditions: Obesity; Type2 Diabetes

Summary: the purpose of this study is to investigate a persons dietary intake and its effect on the gut microbiome and the association of those two variables on weight and glucoregulation. specifically, the investigators will compare the gut microbiota, fasting glucose and insulin, c-peptide and hemoglobin a1-c in three groups of subjects: obese patients (bmi ≥ 30 kg/m2) with type 2 diabetes mellitus (t2dm), obese patients without t2dm, and normal weight lean controls without t2dm. each patient will also complete a detailed dietary recall (asa-24) to investigate the association with diet, microbiome and weight/glucoregulation.


Eligibility criteria:
inclusion criteria: 1. female 2. age 18-65 (inclusive, at time of informed consent) 3. bmi ≥ 30 kg/m2 with t2dm 4. bmi ≥ 30 kg/m2 without t2dm 5. normal weight lean controls without t2dm exclusion criteria: 1. tobacco use in past three months - will add unnecessary confound to the data. 2. taking a medication on a routine/recent basis which is known to significantly influence gastrointestinal transit time or affect the microbiome or other variables significantly (as determined by study pharmacist/md) 3. has taken an oral or injectable antibiotic in the past 3 months 4. has taken a commercially prepared probiotic and/or prebiotic agent in the 3 months 5. history of significant intestinal disease or disorder (e.g., crohn's disease, ulcerative colitis) 6. history of gastrointestinal surgery that may impact measures of biological variables, as determined by the investigator 7. medical condition expected to impact the biological variables of interest or interfere with providing a sample, as determined by the investigator. 8. unable to speak/read english 9. breastfeeding, pregnant, or planning to become pregnant within the duration of the study as assessed through self-report on medical history 10. unwilling to use a medically acceptable form of contraception during study involvement. medically acceptable forms of contraception include oral contraception, physical barrier methods and/or abstinence. 11. any known infectious disease such as viral hepatitis or hiv (as determined by study pharmacist/md)
pharmacoeconomic assessment iressa® in the treatment of non-small-cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: the objective of this pharmacoeconomics (pe) study is to evaluate the cost- effectiveness analysis and cost-utility analysis of iressa® as first line treatment of nsclc from the society perspective, based on resources and outcomes from patients who met the inclusion criteria for this naturalistic study comparing to existing first line platinum-based regimen chemotherapy.

patients with late-stage nsclc are often symptomatic, with specific pulmonary problems (eg, cough, breathlessness, hemoptysis) and general symptoms (eg. fatigue, weight loss) that can cause extreme distress to the patient. therefore, improvements in disease-related symptoms and quality of life (qol) are the key desired outcomes of medical management.7 effective, palliative, low-toxicity with reasonable treatment cost for patients with advanced nsclc are needed. recently, more and more countries consider evidence of economic value along with clinical efficacy. the epidermal growth factor receptor (egfr) is a promising target for anticancer therapy because it is expressed or highly expressed in a variety of tumors, including nsclc. 8,9 furthermore, high levels of egfr expression have been associated with a poor prognosis in lung cancer patients in several studies. 10-12 egfr-targeted cancer therapies are currently being developed; strategies include inhibition of the intracellular tyrosine kinase domain of the receptor by small molecules such as gefitinib (iressa \[zd1839\]; astrazeneca, wilmington, de).13 iressa is an orally active, selective egfr tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage iiib/iv nsclc no immediate need for palliative radiotherapy and no prior chemotherapy ; age \> 20 y/o; ecog ps: 0 - 2; anc \>2000 ; plt \>100k ; hb \> 10; total bilirubin \ 6mos exclusion criteria: * if the patients have brain metastases or receive radiotherapy, the disease must be stable for more than 6 weeks after the last dose of radiotherapy; * 2nd malignancies; * unable to swallow tablets; * patients (m/f) with reproductive potential not implementing adequate contraceptive measurements; * pregnant or lactating patients; * participation in other clinical trials within 30 days of study entry; * major systemic disease which in the investigator's opinion might confound the clinical trial.

Keywords: egfr non-small cell lung cancer
influence of hypoxia on electroretingraphy (erg) measurements

Conditions: ERG Under Hypoxia

Summary: to investigate the influence of induced hypoxia on the erg.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * under 18 and over 80 years, respiratory diseases, cataracta and corneal hazes, myopia more than 6 dpt, hyperopia more than 3 dpt, allergy for any topical anesthetics in ophthalmology, photic epilepsy, asthma bronchiale.
efficiency study to investigate blonanserin in treatment of schizophrenia when compared with risperidone

Conditions: Schizophrenia

Summary: a randomized, double-blinded, double-dummy, parallel-controlled and multicenter clinical trial to investigate blonanserin in treatment of schizophrenia when compared with risperidone

a randomized, double-blinded, double-dummy, parallel-controlled and multicenter clinical trial to investigate blonanserin in treatment of schizophrenia when compared with risperidone trial drugs: * blonanserin group: blonanserin tablets+risperidone mimetic tablets * risperidone group: risperidone tablets+blonanserin mimetic tablets objectives of study : to evaluate the efficacy and safety of blonanserin in treating schizophrenia

Eligibility criteria:
inclusion criteria: * subject met diagnostic and statistical manual of mental disorders(dsm)-iv-text revision(tr) criteria for a primary diagnosis of schizophrenia * patients are 18≤age\<65 years of age on the day when informed consent is obtained. * subject had a panss total score ≥70 and 120≥ at screening * subject had a score ≥4 on the panss at screening and baseline. * subjects are willing and able to comply with study protocol including treatment in hospital. * subjects or their legal guardians have signed the written informed consent form. exclusion criteria: * the subject was treatment with other investigate product within 30 days. * subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days. * subject had a history of treatment with clozapine within 28 days. * subject with parkinson disease,etc

Keywords: blonanserin